202 related articles for article (PubMed ID: 31430592)
21. [The expression level of secretory mature B cell surface antigen in primary diagnosed multiple myeloma and its clinical significance].
Yan Z; Chen GH; Yao WQ; Yan LZ; Jin S; Shang JJ; Shi XL; Wu DP; Fu CC
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2351-2356. PubMed ID: 35970793
[No Abstract] [Full Text] [Related]
22. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
[TBL] [Abstract][Full Text] [Related]
23. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia.
Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR
Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J
Clin Exp Immunol; 2024 May; ():. PubMed ID: 38743453
[TBL] [Abstract][Full Text] [Related]
25. A Computational Pipeline for the Diagnosis of CVID Patients.
Emmaneel A; Bogaert DJ; Van Gassen S; Tavernier SJ; Dullaers M; Haerynck F; Saeys Y
Front Immunol; 2019; 10():2009. PubMed ID: 31543876
[TBL] [Abstract][Full Text] [Related]
26. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
27. Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement.
Lin Z; Yu N; Cheng C; Jin B; Zhang Q; Zhuang H; Jiang X
Lupus; 2023 Apr; 32(5):680-687. PubMed ID: 36914971
[TBL] [Abstract][Full Text] [Related]
28. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
[TBL] [Abstract][Full Text] [Related]
29. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
[TBL] [Abstract][Full Text] [Related]
30. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Common Monogenic Defects in a Large Predominantly Antibody Deficiency Cohort.
Yazdani R; Abolhassani H; Kiaee F; Habibi S; Azizi G; Tavakol M; Chavoshzadeh Z; Mahdaviani SA; Momen T; Gharagozlou M; Movahedi M; Hamidieh AA; Behniafard N; Nabavi M; Bemanian MH; Arshi S; Molatefi R; Sherkat R; Shirkani A; Amin R; Aleyasin S; Faridhosseini R; Jabbari-Azad F; Mohammadzadeh I; Ghaffari J; Shafiei A; Kalantari A; Mansouri M; Mesdaghi M; Babaie D; Ahanchian H; Khoshkhui M; Soheili H; Eslamian MH; Cheraghi T; Dabbaghzadeh A; Tavassoli M; Kalmarzi RN; Mortazavi SH; Kashef S; Esmaeilzadeh H; Tafaroji J; Khalili A; Zandieh F; Sadeghi-Shabestari M; Darougar S; Behmanesh F; Akbari H; Zandkarimi M; Abolnezhadian F; Fayezi A; Moghtaderi M; Ahmadiafshar A; Shakerian B; Sajedi V; Taghvaei B; Safari M; Heidarzadeh M; Ghalebaghi B; Fathi SM; Darabi B; Bazregari S; Bazargan N; Fallahpour M; Khayatzadeh A; Javahertrash N; Bashardoust B; Zamani M; Mohsenzadeh A; Ebrahimi S; Sharafian S; Vosughimotlagh A; Tafakoridelbari M; Rahim M; Ashournia P; Razaghian A; Rezaei A; Samavat A; Mamishi S; Khazaei HA; Mohammadi J; Negahdari B; Parvaneh N; Rezaei N; Lougaris V; Giliani S; Plebani A; Ochs HD; Hammarström L; Aghamohammadi A
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):864-878.e9. PubMed ID: 30240888
[TBL] [Abstract][Full Text] [Related]
32. X-linked Agammaglobulinemia.
Suri D; Rawat A; Singh S
Indian J Pediatr; 2016 Apr; 83(4):331-7. PubMed ID: 26909497
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experience.
Vivarelli E; Matucci A; Bormioli S; Parronchi P; Liotta F; Cosmi L; Almerigogna F; Vultaggio A
Clin Exp Immunol; 2021 Sep; 205(3):346-353. PubMed ID: 34061980
[TBL] [Abstract][Full Text] [Related]
34. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
[TBL] [Abstract][Full Text] [Related]
35. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
J Clin Immunol; 2023 Aug; 43(6):1104-1117. PubMed ID: 37231290
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
[TBL] [Abstract][Full Text] [Related]
37. X-linked agammaglobulinemia diagnosed late in life: case report and review of the literature.
Sigmon JR; Kasasbeh E; Krishnaswamy G
Clin Mol Allergy; 2008 Jun; 6():5. PubMed ID: 18518992
[TBL] [Abstract][Full Text] [Related]
38. The outcome of patients with unclassified hypogammaglobulinemia in early childhood.
Kutukculer N; Gulez N
Pediatr Allergy Immunol; 2009 Nov; 20(7):693-8. PubMed ID: 19196447
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptors pathway in common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA).
Tavasolian P; Sharifi L; Aghamohammadi A; Noorbakhsh F; Sanaei R; Shabani M; Rezaei N
Eur Cytokine Netw; 2018 Nov; 29(4):153-158. PubMed ID: 30698158
[TBL] [Abstract][Full Text] [Related]
40. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
